Skip to content

Advancements in Space Omics

Recent advancements in space omics have ushered in a new era of understanding how spaceflight affects human physiology and biology. The Space Omics and Medical Atlas (SOMA), released in 2024, represents a significant milestone in this field, providing the largest-ever collection of data for aerospace medicine and space biology[2]. SOMA encompasses data from various missions, including the NASA Twins Study, JAXA CFE study, SpaceX Inspiration4 crew, Axiom, and Polaris[4]. This comprehensive resource has led to a more than tenfold increase in publicly available human space omics data, offering unprecedented insights into the molecular and physiological changes that occur during spaceflight[4]. The SOMA package includes 44 publications, with 32 featuring at least one member of the Ames Space Biosciences Division team[2]. This collaborative effort involved over 100 institutions from more than 25 countries, highlighting the global nature of space research[2]. One… 

more »Advancements in Space Omics

MHH: Hospital of maximum care wants to strike

Despite ongoing negotiations regarding relief measures for employees at the Hannover Medical School (MHH), the Verdi union has called its members to a three-day warning strike next week. The strike is scheduled to take place from Wednesday, October 16, 2024, to Friday, October 18, 2024, inclusive. Emergencies will be adequately treated even on strike days. To this end, the MHH has concluded an emergency service agreement with Verdi. However, considerable restrictions may again occur in daily hospital operations on the strike days. This particularly affects planned surgeries, planned inpatient admissions, and outpatient treatments. To avert longer-term restrictions in operating rooms, wards, and outpatient clinics, and their consequences, the legality of the now announced strike is to be clarified by the courts. During a three-day warning strike in September, hundreds of surgeries and treatments had to be postponed or canceled. A planned three-day work stoppage that Verdi planned in August… 

more »MHH: Hospital providing maximum care plans to strike

Liquid biopsy shows amount of tumor DNA in blood

Parallel to staging diagnostics, researchers from Tübingen therefore conducted a study monitoring a new method, the so-called liquid biopsy – a blood test that can be used to detect and analyze circulating tumor DNA in the body. Liquid biopsies are already routinely performed for breast and lung cancer. For malignant melanoma, liquid biopsies are currently only used in individual cases and are not reimbursed by statutory health insurance companies in routine care. However, liquid biopsies are becoming increasingly relevant. "In contrast to PET-CT, it is significantly more cost-effective and can be repeated multiple times in a short period, for example, monthly. Just a few weeks after starting therapy with ICI, the test shows whether the amount of tumor DNA in the blood is decreasing or increasing," explains Prof. Dr. Andrea Forschner, head of the Melanoma Clinic at the University Dermatology Clinic in Tübingen. Together with Dr. Christopher Schroeder from the Institute for Medical Genetics and...

more »Liquid biopsy shows amount of tumor DNA in blood

Why should one read labnews.ai?

  • News

A comprehensive comparison with other websites. labnews.ai/ (LabNews) stands out as a valuable resource for professionals and enthusiasts in the life sciences, biotechnology, and digital health sectors. This US website in German and English offers several compelling reasons to make it a regular part of one's reading routine, especially when compared to other popular biotech news sources. Firstly, labnews.ai/ provides a focused and specialized approach to news coverage. Unlike broader platforms like BioSpace or FierceBiotech, which cover a wide range of biotech and pharmaceutical topics, labnews.ai/ concentrates specifically on laboratory sciences, offering in-depth insights into this crucial area of the life sciences industry[1]. This specialization allows readers to access more targeted and relevant information for those working directly in laboratory settings or closely related fields. The website's commitment to delivering current news and developments is another key advantage. labnews.ai/ keeps…

more »Why should one read labnews.ai?

Intelligent bioroboter to treat prostate cancer

The US Food and Drug Administration (FDA) has granted medical technology company PROCEPT BioRobotics approval to conduct a clinical trial for the treatment of prostate cancer using its AquaBeam Robotic System[1]. This decision marks an important step in the development of new therapeutic options for prostate cancer patients. Innovative technology against a common type of cancer Prostate cancer is the most common cancer in men in Germany. Approximately 65,000 new cases are diagnosed annually[2]. The disease originates from the glandular tissue of the prostate and often remains asymptomatic in its early stages[2]. Risk factors include advanced age and a family history of the disease[4]. PROCEPT BioRobotics' AquaBeam Robotic System uses a combination of imaging, robot-assisted control, and waterjet ablation. This technology enables precise and gentle removal of prostate tissue. Hope for improved treatment options The now-approved study will investigate the efficacy and safety of the system in treating early-stage prostate cancer. Dr. Nikolai Aljuri, founder and CEO… 

more »Intelligent bioroboter to treat prostate cancer

FDA Reports Surge in AI/ML-Enabled Medical Devices

The U.S. Food and Drug Administration (FDA) has announced a significant milestone in the field of artificial intelligence and machine learning (AI/ML) in healthcare. As of August 7, 2024, the agency has authorized a total of 950 AI/ML-enabled medical devices for use in the United States. This remarkable figure underscores the rapid advancement and adoption of AI technologies in the medical field. The FDA has been diligently tracking and evaluating these innovative devices, which span across various medical disciplines. To provide transparency and inform the public, the FDA has compiled a comprehensive list of these authorized AI/ML-enabled devices. This list, which is regularly updated, includes detailed information such as the device name, manufacturer, date of approval, and its primary intended use. The FDA emphasizes that all listed devices have undergone rigorous evaluation to ensure they meet the agency’s stringent safety… 

more »FDA Reports Surge in AI/ML-Enabled Medical Devices

Baxter: Hurricane Helene Update

On October 3, 2024, Baxter provided an update on the impact of Hurricane Helene on their North Cove manufacturing site in Western North Carolina[1]. The facility experienced significant damage due to unprecedented rain and storm surge, resulting in water permeating the site[1]. Baxter’s top priorities are supporting affected employees, restoring the facility, and ensuring continued supply to patients[1]. Site Status While progress has been made since the storm, Baxter does not yet have a specific timeline for resuming operations at North Cove[1]. The company is committed to restarting operations as quickly as possible, with CEO Joe Almeida pledging to spare no resource in this effort[1]. Key Areas of Focus Employees: Baxter has established contact with most of their 2,500+ colleagues but is still working to confirm the well-being of some employees due to cell phone access issues[1]. An employee assistance… 

more »Baxter: Hurricane Helene Update

First-In-Human Early Feasibility Study with Implantable Bladder Device

iota Biosciences, Inc., a wholly-owned subsidiary of Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) for an Early Feasibility Study (EFS). The EFS will evaluate the safety and feasibility of an investigational implantable device designed to deliver electrical stimulation directly to the bladder wall, inducing contractions that facilitate bladder emptying in individuals impacted by underactive bladder (UAB). The FDA granted a staged approval of the EFS for this novel device. The first stage will include enrollment of three participants (at least one male and one female). Following successful safety outcomes from Stage 1, the FDA approved expanding the study to a total of 10 participants. UAB is characterized by a combination of lower urinary tract symptoms related to detrusor underactivity.… 

more »First-In-Human Early Feasibility Study with Implantable Bladder Device

Corona Debrief: The EU's AstraZeneca Disaster

AstraZeneca's coronavirus vaccine, initially hailed as a promising weapon against the pandemic, is now at the center of controversial discussions. On May 7, 2024, AstraZeneca announced that the vaccine is being withdrawn worldwide[1][8]. This followed the company's application on March 5 to revoke the EU marketing authorization[6]. According to AstraZeneca, the main reason for this step is the "overabundance of available updated vaccines" that are more effective against newer virus variants[6][8]. In fact, the risk-benefit assessment has changed significantly since the start of the vaccination campaign. While the vaccine played a crucial role in the early stages of the pandemic and, according to estimates, saved over 6.5 million lives in the first year alone[1], demand decreased with the advent of newer, variant-specific vaccines. A significant factor in the withdrawal was also safety concerns. The AstraZeneca vaccine has been linked to a rare but serious side effect: Thrombosis with Thrombocytopenia Syndrome (TTS)[4][6]. This occurred in about 2-3… 

more »Corona Debrief: The EU's AstraZeneca Disaster

Drosten calls for Corona debrief

Virologist Christian Drosten advocates for a debriefing of the Corona pandemic. "Not working on it now is a missed opportunity," he told the news portal T-Online. In his view, a debriefing does not necessarily have to take place at the political level. "However, society urgently needs one to establish a few things that are now scientifically clearly proven." […] Drosten insists on Corona debriefing